Dr. Stephan Moll provides an update on Charlie the lemur who recently passed away, and shares a thank-you letter sent to him by the Duke Lemur Center.

Dr. Saad Usmani discusses "Empires of the Indus" by Alice Albinia, a nonfiction book about the author's travels along the river.

Dr. Teachey reviews studies that look for therapeutic alternatives to hematopoietic stem cell transplantation in leukemia patients with unfavorable outcomes.

Drs. Wright and Kim discuss a study that examined T cell subset distribution and activating/inhibitory checkpoint receptor-ligand expression in the bone marrow microenvironment of acute myeloid leukemia.

Dr. Boulware and Dr. O'Dwyer discuss a study that tested the efficacy and feasibility of a pediatric regimen for adolescent and young adult patients with newly diagnosed B- or T-lineage Philadelphia chromosome-negative acute lymphoblastic leukemia.

Dr. Osunkwo explores the bidirectional relationship between age, sleep, and pain in youth with sickle cell disease.

Dr. Houghton and Dr. Moll discuss two observational studies that have directly compared apixaban to rivaroxaban for the initial treatment of venous thromboembolism.

Dr. O'Sullivan and Dr. Mead explore causes of therapy-related myeloid neoplasms.

Drs. Rahmat, Sklavenitis-Pistofidis, and Ghobrial review the understanding of thalidomide-CRBN-mediated protein degradation and novel target proteins for thalidomide therapy.

Dr. DeZern reviews two manuscripts observing the clinical experience of eltrombopag for thrombocytopenia post-stem cell transplantation.

Dr. Linkins discusses the use of thrombolysis for treatment of pulmonary embolism in patients with bleeding risk.

Dr. Lane discusses results of a study observing the link between tissue specificity of glucocorticoid response and acquired glucocorticoid resistance in acute lymphoblastic leukemia.

Dr. Gary Lyman examines the safety and efficacy of biosimilars approved by the U.S. Food and Drug Administration.

Dr. Siok-Keen Tey and Dr. Geoffrey Hill explore therapeutic options for treating chronic graft-versus-host disease.

Dr. Fenske and Dr. Kahl discuss a trial enrolling adult patients with mantle cell lymphoma (MCL), who are considered candidates for autologous hematopoietic cell transplantation, to find whether MRD status can be used to personalize therapy in MCL.

Dr. Jacobson reviews a study investigating the safety and efficacy of the anti-CD79b antibody drug conjugate, polatuzumab, in combination with R-CHP versus R-CHOP in previously untreated patients with DLBCL.

Dr. Martin Tallman pays tribute to friend and colleague, Italian acute promyelocytic leukemia expert, Dr. Francesco Lo Coco, who passed away on March 3, 2019.

Dr. Silverstein discusses the Society's efforts to help hematologists become effective teachers and preachers of continuous quality improvement.

Drs. Andrea Cervi, Artemis Diamantouros, and Madeleine Verhovsek provide commentary on the implications of assigning a "hazardous drug" label to hydroxyurea.

Take this image challenge from Drs. Kaumeyer, Arber, and Venkataraman featuring an older man with cytopenias after treatment of a previously diagnosed hematologic malignancy. Ancillary studies including molecular testing were needed to arrive at the diagnosis.

ASH Committee on Practice Chair Dr. Joseph Alvarnas discusses issues faced by practicing hematologists and why it is important for physicians to have their voices heard by policymakers.